Cargando…

Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?

As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineeri...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Bano, Joanie, Chames, Patrick, Baty, Daniel, Kerfelec, Brigitte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698871/
https://www.ncbi.nlm.nih.gov/pubmed/31557983
http://dx.doi.org/10.3390/antib5010001
_version_ 1783444632514854912
author Del Bano, Joanie
Chames, Patrick
Baty, Daniel
Kerfelec, Brigitte
author_facet Del Bano, Joanie
Chames, Patrick
Baty, Daniel
Kerfelec, Brigitte
author_sort Del Bano, Joanie
collection PubMed
description As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineering and the development of several technological platforms such as Triomab or bispecific T cell engagers (BiTEs), the “bispecifics” market has increased significantly over the past decade and may occupy a pivotal space in the future. Over 30 bispecific molecules are currently in different stages of clinical trials and more than 70 in preclinical phase. This review focuses on the clinical potential of bispecific antibodies as immune effector cell engagers in the onco-immunotherapy field. We summarize current strategies targeting various immune cells and their clinical interests. Furthermore, perspectives of bispecific antibodies in future clinical developments are addressed.
format Online
Article
Text
id pubmed-6698871
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66988712019-09-05 Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? Del Bano, Joanie Chames, Patrick Baty, Daniel Kerfelec, Brigitte Antibodies (Basel) Review As evidenced by the recent approvals of Removab (EU, Trion Pharma) in 2009 and of Blincyto (US, Amgen) in 2014, the high potential of bispecific antibodies in the field of immuno-oncology is eliciting a renewed interest from pharmaceutical companies. Supported by rapid advances in antibody engineering and the development of several technological platforms such as Triomab or bispecific T cell engagers (BiTEs), the “bispecifics” market has increased significantly over the past decade and may occupy a pivotal space in the future. Over 30 bispecific molecules are currently in different stages of clinical trials and more than 70 in preclinical phase. This review focuses on the clinical potential of bispecific antibodies as immune effector cell engagers in the onco-immunotherapy field. We summarize current strategies targeting various immune cells and their clinical interests. Furthermore, perspectives of bispecific antibodies in future clinical developments are addressed. MDPI 2015-12-26 /pmc/articles/PMC6698871/ /pubmed/31557983 http://dx.doi.org/10.3390/antib5010001 Text en © 2015 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Del Bano, Joanie
Chames, Patrick
Baty, Daniel
Kerfelec, Brigitte
Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
title Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
title_full Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
title_fullStr Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
title_full_unstemmed Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
title_short Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?
title_sort taking up cancer immunotherapy challenges: bispecific antibodies, the path forward?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698871/
https://www.ncbi.nlm.nih.gov/pubmed/31557983
http://dx.doi.org/10.3390/antib5010001
work_keys_str_mv AT delbanojoanie takingupcancerimmunotherapychallengesbispecificantibodiesthepathforward
AT chamespatrick takingupcancerimmunotherapychallengesbispecificantibodiesthepathforward
AT batydaniel takingupcancerimmunotherapychallengesbispecificantibodiesthepathforward
AT kerfelecbrigitte takingupcancerimmunotherapychallengesbispecificantibodiesthepathforward